Cellectis S.A. Files Routine 6-K Report
Ticker: CLLS · Form: 6-K · Filed: May 6, 2025 · CIK: 1627281
| Field | Detail |
|---|---|
| Company | Cellectis S.A. (CLLS) |
| Form Type | 6-K |
| Filed Date | May 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, routine-report, foreign-private-issuer
TL;DR
Cellectis filed a 6-K, just a routine update, no big news.
AI Summary
Cellectis S.A. filed a Form 6-K on May 6, 2025, to report its activities as a foreign private issuer for the month of May 2025. The company, based in Paris, France, is involved in the biological products sector. This filing is routine and does not disclose specific financial or operational updates beyond its periodic reporting obligation.
Why It Matters
This filing indicates Cellectis S.A. is fulfilling its ongoing reporting requirements as a foreign private issuer with the SEC. It does not contain new material information.
Risk Assessment
Risk Level: low — This is a routine filing to comply with SEC reporting requirements for foreign private issuers and does not contain new material information.
Key Players & Entities
- Cellectis S.A. (company) — Registrant
- Paris, France (location) — Company Headquarters
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the issuer would be required to disclose to its security holders or make public in its country of origin.
When was this Form 6-K filed?
This Form 6-K was filed on May 6, 2025.
What is Cellectis S.A.'s primary business sector?
Cellectis S.A. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
Does Cellectis S.A. file annual reports under Form 20-F?
Yes, the filing indicates Cellectis S.A. files annual reports under cover of Form 20-F.
Where is Cellectis S.A. headquartered?
Cellectis S.A. is headquartered at 8, rue de la Croix Jarry, 75013 Paris, France.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 6, 2025 regarding Cellectis S.A. (CLLS).